Bio-Cancer Treatment International Limited

BCT’s product candidate portfolio comprises BCT-100 and BCT-200, both pegylated recombinant human arginase 1 (pegArg1). They are arginine depleting agents that retard tumour growth and ultimately lead to cancer death. BCT-100 is currently in phase I clinical trial in the US for the treatment of arginine-auxotrophic solid cancers and phase II clinical trial in the United Kingdom for the treatment of acute myeloid leukaemia (AML), in combination with low dose cytarabine, in elderly patients and in sarcomas, AML and neuroblastoma in paediatric patients.